Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TCDA Stock Summary
In the News
Tricida files for Chapter 11 bankruptcy protection as it searches for a buyer
Tricida Inc., a clinical-stage pharmaceutical company working on a kidney disease drug, has filed for Chapter 11 bankruptcy protection in Delaware, with roughly US$350 million of debt, according to a court filing. The San Francisco-based company will try to sell itself out of bankruptcy and has signed a restructuring support agreement (RSA) with 80% of its convertible noteholders, according to court papers.
Top 10 most-shorted stocks as of November 2022
The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among investors have been especially unsettling for companies with weak financial positions.
What Penny Stocks Industries Are Popular Right Now?
These industries could be worth looking into to find penny stocks to watch The post What Penny Stocks Industries Are Popular Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Look For in Penny Stocks Under $1, 3 Tips
Trading under $1 penny stocks? Use these tips The post What to Look For in Penny Stocks Under $1, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Buying Cheap Penny Stocks in November? 3 Tips to Use
Check these tips out for trading penny stocks right now The post Buying Cheap Penny Stocks in November? 3 Tips to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Reasons You're Not Making Money With Penny Stocks
Are these the reasons you're not profiting with penny stocks? The post Top Reasons You're Not Making Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Tricida (TCDA) Stock Down 90% Today?
Tricida (NASDAQ: TCDA ) stock is falling on Monday following the release of poor results from a Phase 3 clinical trial. That trial covers the use of veverimer to treat patients suffering from metabolic acidosis and chronic kidney disease (CKD).
Tricida: Important Binary Event Coming Up
TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on.
Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company's key initiatives. The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 12, 2022 at 4:30 pm PT / 1:30 pm ET. An archive of the presentation will be available for 90 days following the presenta
Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q2 2022 Results - Earnings Call Transcript
Tricida, Inc. (NASDAQ:TCDA ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jackie Cossmon - VP of IR & Communications Gerrit Klaerner - Founder, President, CEO & Executive Director Geoffrey Parker - COO, CFO & EVP Conference Call Participants Eva Privitera - Cowen and Company Serge Belanger - Needham & Company Jessica Fye - JPMorgan Chase & Co. Operator Ladies and gentlemen, thank you for standing by, and welcome to the Tricida Second Quarter 2022 Financial Results Conference Call. [Operator Instructions].
TCDA Financial details
TCDA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -7.53 | -4.64 | -3.72 | -5.29 | -3.88 | |
Operating cash flow per share | -7.37 | -4.28 | -2.73 | -4.62 | -2.8 | |
Free cash flow per share | -7.55 | -4.32 | -2.76 | -4.65 | -2.8 | |
Cash per share | 12.33 | 10.89 | 6.48 | 6.19 | 2.81 | |
Book value per share | 10.8 | 8.78 | 5.55 | 2.18 | 0 | |
Tangible book value per share | 10.8 | 8.78 | 5.55 | 1.45 | 0 | |
Share holders equity per share | 10.8 | 8.78 | 5.55 | 2.18 | 0 | |
Interest debt per share | 0 | 1.58 | 1.37 | 0.67 | 3.18 | |
Market cap | 142.55M | 522.21M | 1.79B | 352.7M | 478.27M | |
Enterprise value | 132.69M | 727.01M | 1.83B | 229.96M | 598.7M | |
P/E ratio | -3.45 | -5.08 | -10.14 | -1.33 | -2.46 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.53 | -5.51 | -13.84 | -1.53 | -3.41 | |
PFCF ratio | -3.44 | -5.46 | -13.69 | -1.52 | -3.41 | |
P/B Ratio | 2.41 | 2.68 | 6.8 | 3.24 | 2.19K | |
PTB ratio | 2.41 | 2.68 | 6.8 | 3.24 | 2.19K | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.24 | -7.11 | -10.83 | -0.94 | -3.78 | |
EV to operating cash flow | -3.28 | -7.66 | -14.15 | -0.99 | -4.27 | |
EV to free cash flow | -3.2 | -7.6 | -14 | -0.99 | -4.27 | |
Earnings yield | -0.29 | -0.2 | -0.1 | -0.75 | -0.41 | |
Free cash flow yield | -0.29 | -0.18 | -0.07 | -0.66 | -0.29 | |
Debt to equity | 0 | 0.2 | 0.23 | 0.14 | 649.28 | |
Debt to assets | 0 | 0.15 | 0.16 | 0.05 | 0.84 | |
Net debt to EBITDA | 0.24 | -2 | -0.24 | 0.5 | -0.76 | |
Current ratio | 6.19 | 16.51 | 7.87 | 9.17 | 4.94 | |
Interest coverage | 0 | 33.02 | -31.13 | -13.66 | -9.03 | |
Income quality | 0.98 | 0.92 | 0.73 | 0.87 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -3 | -1.38 | -0.83 | -1.79 | -0.22 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 42.78 | 30.29 | 21.56 | 16.1 | 0.62 | |
ROIC | -0.91 | -0.45 | -0.54 | -1.84 | -1.12 | |
Return on tangible assets | -0.58 | -0.41 | -0.48 | -0.84 | -1.15 | |
Graham Net | 10.24 | 8.48 | 4.21 | 1.33 | -0.55 | |
Working capital | 58.29M | 229.54M | 272.98M | 279.76M | 116.06M | |
Tangible asset value | 59.22M | 194.53M | 263.88M | 72.31M | 218K | |
Net current asset value | 58.07M | 191.02M | 204.8M | 71.2M | -22.75M | |
Invested capital | 0 | 0.2 | 0.23 | 0.14 | 649.28 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.98M | 6.16M | 7.19M | 4.71M | 6.77M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.7 | -0.53 | -0.67 | -2.43 | -890.68 | |
Capex per share | -0.18 | -0.04 | -0.03 | -0.03 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.79 | -1 | -0.55 | -0.53 | -0.48 | |
Operating cash flow per share | -0.57 | -0.7 | -0.46 | -0.44 | -0.32 | |
Free cash flow per share | -0.57 | -0.7 | -0.46 | -0.44 | -0.32 | |
Cash per share | 2.91 | 2.6 | 2.14 | 1.71 | 1.38 | |
Book value per share | 0.04 | 0 | -1.56 | -1.92 | -2.35 | |
Tangible book value per share | 0.04 | 0 | -1.56 | -1.92 | -2.35 | |
Share holders equity per share | 0.04 | 0 | -1.56 | -1.92 | -2.35 | |
Interest debt per share | 2.85 | 2.69 | 3.65 | 3.64 | 3.62 | |
Market cap | 234.02M | 517.31M | 474.45M | 559.75M | 608.01M | |
Enterprise value | 356.7M | 637.74M | 665.21M | 745.84M | 798.26M | |
P/E ratio | -1.47 | -2.39 | -3.75 | -4.59 | -5.48 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -8.1 | -13.59 | -17.97 | -21.88 | -32.43 | |
PFCF ratio | -8.1 | -13.58 | -17.97 | -21.88 | -32.43 | |
P/B Ratio | 123.04 | 2.37K | -5.25 | -5.03 | -4.47 | |
PTB ratio | 123.04 | 2.37K | -5.25 | -5.03 | -4.47 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -10.02 | -13.92 | -24.12 | -28.16 | -33.67 | |
EV to operating cash flow | -12.35 | -16.76 | -25.2 | -29.15 | -42.58 | |
EV to free cash flow | -12.35 | -16.75 | -25.2 | -29.15 | -42.57 | |
Earnings yield | -0.17 | -0.1 | -0.07 | -0.05 | -0.05 | |
Free cash flow yield | -0.12 | -0.07 | -0.06 | -0.05 | -0.03 | |
Debt to equity | 73.43 | 649.28 | -2.31 | -1.87 | -1.53 | |
Debt to assets | 0.85 | 0.84 | 1.48 | 1.82 | 2.22 | |
Net debt to EBITDA | -3.45 | -2.63 | -6.92 | -7.03 | -8.02 | |
Current ratio | 5.88 | 4.94 | 5.12 | 5.11 | 4.87 | |
Interest coverage | -8.94 | -11.28 | -14.02 | -13.44 | -12.02 | |
Income quality | 0.73 | 0.76 | 0.89 | 0.9 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.25 | 0 | 0 | -0.04 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.82 | 0.3 | 4.39 | 4.78 | 5.02 | |
ROIC | -0.23 | -0.32 | -0.22 | -0.26 | -0.3 | |
Return on tangible assets | -0.24 | -0.32 | -0.23 | -0.27 | -0.3 | |
Graham Net | -0.32 | -0.51 | -1.85 | -2.19 | -2.58 | |
Working capital | 125.44M | 116.06M | 103M | 82.33M | 65.56M | |
Tangible asset value | 1.9M | 218K | -90.3M | -111.22M | -136.1M | |
Net current asset value | -11.51M | -22.75M | -102.72M | -123.13M | -147.49M | |
Invested capital | 73.43 | 649.28 | -2.31 | -1.87 | -1.53 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3M | 6.64M | 7.78M | 4.64M | 4.07M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -20.86 | -247.91 | 0.35 | 0.27 | 0.2 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
TCDA Frequently Asked Questions
What is Tricida, Inc. stock symbol ?
Tricida, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol TCDA
Is Tricida, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $19. The lowest prediction is $16 and the highest is $22
What is TCDA stock prediction ?
What is Tricida, Inc. stock quote today ?
Tricida, Inc. stock price is $- today.
Is Tricida, Inc. stock public?
Yes, Tricida, Inc. is a publicly traded company.